Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's the shorts who have their math wrong.
They are trying to instill doubt. The power of A-273 is too great.
Anavex ushers in a new standard of care! What a headline.
I believe the timeline for a FDA response is 45 days.
Real analysts will soon pick up on today's great news.
AF by another name.lol
Yep we got this. A-273 is the real deal. ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks. Biogen received approval at 27%.
News will just get out people talk others listen. Media will most likely spread it. It brings hope.There may even be a interview or two. This is big time stuff.
Medicare will jump on this due to the cost savings. A pill would be covered under a prescription drug plan not regular medicare.
That's right thank you Lord!!!
Ditto! Significant news!! Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL
Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results
Plan to Meet with Regulatory Authorities to Determine Next Steps
Wow Remdesiver causes acute kidney injury. No thank you! One thing to note is remdesiver failed miserably it's first covid-19 trial. B needs another fair shot.
Roche presented full results of twin trials at an Alzheimer's meeting in San Francisco after announcing in November that the drug had failed in the two trials.
So failure was announced prior to CTAD. AVXL up next.
Thanks. I see the chart displays Anavex 3-71 for AD so no changes. Good to see.
He clearly has the data and more.
“This is an exciting time in neuroscience and rare disease drug development and we remain on track for the readout of the placebo-controlled ANAVEX®2-73 Phase 2b/3 Alzheimer’s disease clinical trial, a condition of significant unmet need and economic burden for which there are only limited approved pharmacological treatment options,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Our recent progress highlights the potential of our clinical Precision Medicine SIGMAR1 platform and portfolio, and we look forward to sharing additional program and data updates.”
Nice to see this paper. Thanks StockJumper!
https://cbdstconference.com/wp-content/uploads/2022/09/2022CBDSTconference-abstract-363.pdf
Most of the 509 P2B/3 trial participants have enrolled in the open label extension. Why would they... why would care givers keep on with it. Easy answer to me is because of the benefit it provides.
Picked up some today also sure didn't expect this kneecapping though. A good opportunity for new investors to get in. Looking forward to data.
"New nasal therapies utilizing low cost, broad-spectrum molecules like NO are being
developed and other antiviral nasal sprays have also been shown to have anti-COVID-19
activity in clinical trials, including the mimetic antimicrobial peptide, brilacidin, and
astrodimer sodium [18,65,66]. Now is the time for conventional medicine and health
watchdogs like WHO to realize these sprays have the potential for global use, including
poorer counties, to reduce the burden of COVID-19 and thus the incidence of new
devastating variants and waves of disease".
One very important factor I think is cost saving which is very important to Medicare and could work in our favor. A pill formula vs Lecanemab outpatient infusion would save thousands of dollars per patient per year. Right now Medicare is struggling to keep costs under control and would welcome an effective prescription Alzheimer's treatment with open arms. Medicare premiums went up because of the high costs associated with Lecanemab.
That's it in a nutshell Pete. I think we see more good news in the combination anti fungal studies. "Following an in vitro drug screening of 1,402 compounds, Brilacidin showed promising antifungal activity and was subsequently selected for additional pre-clinical evaluation, including in combination with caspofungin (CAS), voriconazole (VOR), and posaconazole (POSA), all current antifungal treatments".
Many thanks for that recommendation. I see it's also on the Freevee app.
Looking forward to seeing what the final nasal formula looks like also more on the anti fungal. Happy Thanksgiving!
There is a world Antivirus conference in San Diego 28 NOVEMBER - 1 DECEMBER 2022.
https://www.terrapinn.com/conference/world-antiviral-congress/index.stm
The HHS Secretary who oversees the PREP Act (COVID-19 Emergency Declarations) specified it is to stay in place till October 1, 2024. Still plenty of time.
I don't believe the government has bought or owned a company outright either at least in modern day.. The instances of the US government owning a company was either by loan guarantee or shares owned such as with Chrysler.
This is bio-level3 research stuff where money is already allocated for these studies. Your confusing this with pet studies.
I should have inputted "rather then buying the company outright" the government would be more inclined to support development such as with BARDA. For one we have government funding through George Mason University now.
You would likely see the government supporting development then buying the company outright.
This could certainly be true of Dr. Missling. I've been invested/following this stock since 2015 and for what I remember he always waits till the morning of a conference before sending the press release. We shall see.
Something the average layperson/investor may not understand is the importance of releasing date to the scientific community in a respectful manner, it is not about shareholders. In true scientists, there is an implicit oath to further knowledge in a manner that would be most beneficial to humanity. Certain conferences are considered much more sacrosanct than others.
Hoping I caught the bottom this time. Looking forward to seeing PDD improvements correlating into the Alzheimer's study. But not only that..
Looking forward to more anti-fungal news! Seems a lot of need in that space. B as a topical would be good to see.
Yesterday-- Cramer said Anavex Life Sciences Corp "another one that I kind of like, I’ve got to tell you." However, he added, "I do not like losses in tech, but in biotech I can accept the fact that they have a good pipeline."
https://www.benzinga.com/trading-ideas/long-ideas/22/11/29720996/this-stock-is-up-106-in-2022-and-analysts-love-it-but-jim-cramer-says-theres-too-much-po
I never seen so much concern.lol Go B novel antifungal agent.
Thanks saw it here. Posted Nov. 15, 2022 7:30 AM ET
Source: Innovation Pharmaceuticals Inc
https://www.newmediawire.com/news
https://www.newmediawire.com/news/scientific-poster-on-innovation-pharmaceuticals-brilacidin-to-be-presented-at-2022-chemical-and-biological-defense-science-technology-conference-7059791
A lot companies on there.
Saw the drop was able to pick up another nice chunk in the $13.80 range. I'm not the only one who thinks we go much higher from here. Buying the dips.
I'm not even counting on the anti-viral any longer. Anti-fungal is a fairly clear field and may even be a better fit for B but we'll see. The question I have is what is Leo doing.
Market? I'm not even looking that far ahead. I'm hoping for more funding and a clinical trial plus caspofungin. Something to kick this tub in the rear.
https://newsfilter.io/a/7824559bc228d1a7b61ae5e5891ec970
10Q Interesting antifungal findings. Hopefully we have results that puts B in human studies.
"Antifungal - Recent data generated from independent researchers suggest Brilacidin has potential to be developed as a novel antifungal agent. Brilacidin converted caspofungin from a fungistatic into a fungicidal drug, enabling it to overcome both drug resistance and biofilm formation. Brilacidin exerted, to a lesser degree, synergistic effects with voriconazole in A. fumigatus. Further in vitro testing showed Brilacidin synergized with caspofungin in C. albicans, C. auris and C. neoformans. In an A. fumigatus immunosuppressed mouse model in invasive pulmonary aspergillosis, Brilacidin plus caspofungin cleared infection in the lungs by almost 95 percent, compared to ~50 percent when each compound was administered individually. Brilacidin also showed in vitro an additive inhibitory effect when combined with posaconazole in several species of Mucorales, the main etiological agents of mucormycosis, commonly referred to as black fungus. Brilacidin further showed potent in vitro stand-alone efficacy in C. neoformans, a major driver of illness in people living with HIV/AIDS".
Here's one you missed.Good info.
https://www.ipharminc.com/brilacidin-1